Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.
NCT ID: NCT07014280
Last Updated: 2025-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE4
28 participants
INTERVENTIONAL
2023-09-01
2025-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Botulinum Toxin Type a Injection to Prevent Keloid Recurrence
NCT05072821
Analysis of Safety and Tissue Interaction of Injectable and Energy-based Biosmulators
NCT06993558
Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy
NCT04827875
Subcision Followed by Diluted Calcium Hydroxylapatite Injection Versus Subcision Followed by Painting CROSS TCA Technique for the Treatment of Atrophic Acne Scars
NCT07028567
Evaluation of the Efficacy and Safety of Microneedling Combined With Botulinum Toxin-A Versus Meso-Botox Injection in the Treatment of Atrophic Acne Scars: A Split-face Comparative Study
NCT06544993
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intralesional bevacizumab injection
Intralesional bevacizumab injection for the treatment of keloid
Bevacizumab
anti-VEGF
Intralesional corticosteroid injection
Intralesional triamcinolone acetonide injection for the treatment of keloids
Triamcinolone Acetonide
corticosteroid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
anti-VEGF
Triamcinolone Acetonide
corticosteroid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>18 years
* Patients who didn't receive any treatment for the lesions in the past 6 weeks
Exclusion Criteria
* History of any liver or renal disease
* History of any cardiovascular disease
* History of hypertension
* History of thrombo-embolic events
* Known cases of bleeding disorders
* History of peptic ulcer
* Patients who underwent any surgeries in the last month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasr El Aini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rana F Hilal, MD
Assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr El Ainy University Hospital, faculty of medicine, Cairo university
Cairo, El Manial, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BevaVSsteroid:keloids
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.